The Role of microRNAs in the Cisplatin- and Radio-Resistance of Cervical Cancer

The Role of microRNAs in the Cisplatin- and Radio-Resistance of Cervical Cancer

Cervical cancer is the fourth leading cause of cancer-related death among women worldwide. The chemotherapeutical agent cisplatin, a small platinum-based compound, is considered as the standard therapy for locally advanced cervical cancer or recurrent cancers, sometimes in combination with radiother...

Full description

Bibliographic Details
Main Authors:	Rina Masadah, Syahrul Rauf, Muhammad Yogi Pratama, Claudio Tiribelli, Devis Pascut
Format:	Article
Language:	English
Published:	MDPI AG 2021-03-01
Series:	Cancers
Subjects:	cervical cancer cisplatin microRNA drug resistance radiotherapy cisplatin resistance
Online Access:	https://www.mdpi.com/2072-6694/13/5/1168

Similar Items

MicroRNAs as the critical regulators of cisplatin resistance in gastric tumor cells
by: Amir Sadra Zangouei, et al.
Published: (2021-06-01)

MicroRNAs as the critical regulators of Cisplatin resistance in ovarian cancer cells
by: Meysam Moghbeli
Published: (2021-09-01)

MicroRNAs as the critical regulators of autophagy-mediated cisplatin response in tumor cells
by: Faezeh Tolue Ghasaban, et al.
Published: (2023-04-01)

Analyzing the whole-transcriptome profiles of ncRNAs and predicting the competing endogenous RNA networks in cervical cancer cell lines with cisplatin resistance
by: Huimin Lv, et al.
Published: (2021-10-01)

Recent advances in the contribution of noncoding RNAs to cisplatin resistance in cervical cancer
by: Xin Wen, et al.
Published: (2020-05-01)

Leonurine Promotes Cisplatin Sensitivity in Human Cervical Cancer Cells Through Increasing Apoptosis and Inhibiting Drug-Resistant Proteins
by: Lin M, et al.
Published: (2020-05-01)

MicroRNAs as the pivotal regulators of cisplatin resistance in head and neck cancers
by: Faezeh Tolue Ghasaban, et al.
Published: (2023-08-01)

Molecular mechanisms of cisplatin resistance in cervical cancer
by: Zhu H, et al.
Published: (2016-06-01)

Transcriptome profiling of cervical cancer cells acquired resistance to cisplatin by deep sequencing
by: Yamin Wang, et al.
Published: (2019-12-01)

Novel composite drug delivery system as a novel radio sensitizer for the local treatment of cervical carcinoma
by: Shan Xu, et al.
Published: (2017-01-01)

Role of microRNA-4739 in enhancing cisplatin chemosensitivity by negative regulation of RHBDD2 in human cervical cancer cells
by: Yuling Li, et al.
Published: (2024-01-01)

Conventional chemoradiation with Cisplatin Versus hemoradiation with Cisplatin plus Gemcitabine in uterine cervical cancer
by: Ahmad Ameri (MD), et al.
Published: (2008-10-01)

Silencing HOXB7 inhibits metastasis and increases the sensitivity to cisplatin in human cervical cancer CASKI cells
by: SUN Hui-xia, GUO Zhe, XU Jing
Published: (2020-04-01)

Combined treatment of marizomib and cisplatin modulates cervical cancer growth and invasion and enhances antitumor potential in vitro and in vivo
by: Ziruizhuo Zhang, et al.
Published: (2022-08-01)

MicroRNA-217 Acts as a Tumor Suppressor and Correlates with the Chemoresistance of Cervical Carcinoma to Cisplatin [Retraction]
by: Yin Z, et al.
Published: (2023-06-01)

Can Cisplatin Therapy Be Improved? Pathways That Can Be Targeted
by: Reem Ali, et al.
Published: (2022-06-01)

The Influence of Cisplatin Dose upon Survival in Concurrent Chemoradiotherapy of Locally Advanced Cervical Carcinoma with Weekly Cisplatin
by: Igor Sirák, et al.
Published: (2008-01-01)

linc00958/miR-185-5p/RSF-1 modulates cisplatin resistance and angiogenesis through AKT1/GSK3β/VEGFA pathway in cervical cancer
by: Jing Tian, et al.
Published: (2022-09-01)

Long term results of comparison of concurrent low-dose daily cisplatin versus the standard weekly cisplatin with six fractions per week radiotherapy in locally advanced head neck cancer
by: Pramod Kumar Gupta, et al.
Published: (2016-01-01)

Treatment outcomes of concurrent weekly cisplatin with intracavitary brachytherapy in patients with cervical carcinoma, pre-treated with concurrent chemo-radiotherapy
by: Swapan K Mallick, et al.
Published: (2022-01-01)

Combination of Niraparib, Cisplatin and Twist Knockdown in Cisplatin-Resistant Ovarian Cancer Cells Potentially Enhances Synthetic Lethality through ER-Stress Mediated Mitochondrial Apoptosis Pathway
by: Entaz Bahar, et al.
Published: (2021-04-01)

ROS-Induced DCTPP1 Upregulation Contributes to Cisplatin Resistance in Ovarian Cancer
by: Yu Wang, et al.
Published: (2022-02-01)

MicroRNA-218 regulates the chemo-sensitivity of cervical cancer cells through targeting survivin
by: Yu M, et al.
Published: (2019-07-01)

Targeting DNA Damage Response and Repair to Enhance Therapeutic Index in Cisplatin-Based Cancer Treatment
by: Robert Csaba Kiss, et al.
Published: (2021-07-01)

Gene Promoter-Methylation Signature as Biomarker to Predict Cisplatin-Radiotherapy Sensitivity in Locally Advanced Cervical Cancer
by: Carlos Contreras-Romero, et al.
Published: (2022-03-01)

High Risk α-HPV E6 Impairs Translesion Synthesis by Blocking POLη Induction
by: Sebastian O. Wendel, et al.
Published: (2020-12-01)

Diclofenac Sensitizes Signet Ring Cell Gastric Carcinoma Cells to Cisplatin by Activating Autophagy and Inhibition of Survival Signal Pathways
by: Nang Lae Lae Phoo, et al.
Published: (2022-10-01)

Molecular Networks of Platinum Drugs and Their Interaction with microRNAs in Cancer
by: Shihori Tanabe, et al.
Published: (2023-11-01)

Cisplatin Induced Nephrotoxicity
by: Seyed Seifollah Beladi Mousavi, et al.
Published: (2014-02-01)

Cisplatin in Ovarian Cancer Treatment—Known Limitations in Therapy Force New Solutions
by: Aleksandra Zoń, et al.
Published: (2023-04-01)

Efficacy of cisplatin-based combinations in chemoradiation therapy of cervical cancer
by: I Ya Bazaeva, et al.
Published: (2015-09-01)

Cisplatin Resistance: Genetic and Epigenetic Factors Involved
by: Yuliannis Lugones, et al.
Published: (2022-09-01)

A Phase Ib Study of Durvalumab (MEDI4736) in Combination with Carbon-Ion Radiotherapy and Weekly Cisplatin for Patients with Locally Advanced Cervical Cancer (DECISION Study): The Early Safety and Efficacy Results
by: Noriyuki Okonogi, et al.
Published: (2023-06-01)

Effects of cisplatin in cervical cancer cells /
by: Siti Khairunnisa Ishak, 1993-, author 609192, et al.
Published: (2016)

Effects of cisplatin in cervical cancer cells /
by: Siti Khairunnisa Ishak, 1993-, author 609192
Published: (2016)

Graphene Oxide Enhanced Cisplatin Cytotoxic Effect in Glioblastoma and Cervical Cancer
by: Kacper Kregielewski, et al.
Published: (2023-08-01)

EHHADH contributes to cisplatin resistance through regulation by tumor-suppressive microRNAs in bladder cancer
by: Shunsuke Okamura, et al.
Published: (2021-01-01)

The Down-Regulation of MicroRNA-497 Contributes to Cell Growth and Cisplatin Resistance Through PI3K/Akt Pathway in Osteosarcoma
by: Xue-jun Shao, et al.
Published: (2015-07-01)

Determining the Potential of DNA Damage Response (DDR) Inhibitors in Cervical Cancer Therapy
by: Santu Saha, et al.
Published: (2022-09-01)

The Crosstalk between Tumor Cells and the Microenvironment in Hepatocellular Carcinoma: The Role of Exosomal microRNAs and Their Clinical Implications
by: Devis Pascut, et al.
Published: (2020-03-01)